#Taiwan #Taipei #Clinical Trials #HanchorBio #HCB101

HanchorBio's Upcoming Listing on the Taiwan Innovation Board

HanchorBio, Inc. (TPEx: 7827), a prominent player in the global clinical-stage biotechnology sector, is gearing up for a significant milestone. The company is set to officially list on the Taiwan Innovation Board on May 29, 2026, with a share price of NT$120. This move comes at a pivotal time as the company emphasizes its commitment to pioneering next-generation immunotherapies aimed at oncology and autoimmune diseases.

About HanchorBio

HanchorBio operates with a primary goal of addressing critical medical needs in immuno-oncology and immune-mediated diseases. The company’s advanced FBDB™ (Fc-based Designer Biologics) platform is designed to integrate various immune-modulating mechanisms into single functional entities. This unique approach supports the creation of multi-target, multifunctional therapies, which distinguishes HanchorBio in the competitive biotech landscape.

Pipeline of Breakthrough Therapies

The company boasts an impressive pipeline of both clinical and preclinical candidates. Notably, HCB101, the leading candidate, is a CD47-targeting anti-cancer drug that has been meticulously engineered to obstruct signals that enable tumors to evade the immune response. This promising drug is currently under Phase 2a clinical trials, showing potential when combined with treatment options like ramucirumab and paclitaxel for gastric cancer, as well as for other malignancies, including head and neck cancer and triple-negative breast cancer.

In addition to HCB101, HanchorBio is progressing with HCB301, a trifunctional fusion protein already in Phase 1 trials across multiple regions including the United States, China, and Taiwan. Another candidate, HCB303 is undergoing planning for clinical development, while HCB206 targets autoimmune diseases, forming a critical part of the company’s long-term strategy.

Importance of Early Clinical Data

Scott Liu, Ph.D., the founder and CEO of the company, emphasizes that early clinical data plays a vital role in attracting potential global pharmaceutical partners, particularly in licensing and partnership negotiations. HCB101 has already shown encouraging results in initial Phase 1b/2a studies, with a reported objective response rate of 80% in a mid-dose cohort involving gastric cancer. The safety profile and tumor reduction data have also been promising, indicating strong potential for continued development.

Strategic Partnerships and Global Outreach

The strategic direction pursued by HanchorBio involves a multi-indication clinical development approach for HCB101, allowing them to explore various business opportunities including licensing agreements and co-development with renowned global pharmaceutical companies. The recent licensing agreement with Henlius to develop and commercialize HCB101 for mainland China and select regions underscores the company's strategic focus, with a deal possibly worth up to US$202 million. Ongoing discussions with multiple leading global firms further emphasize the broad interests in HCB101 and its potential impact on the market.

Future Prospects

With the upcoming public listing on the Taiwan Innovation Board, HanchorBio aims to enhance its visibility and strategic partnerships on a global scale. The biotechnology firm is focused on leveraging its advanced technologies and promising clinical data to establish significant collaborations that could ultimately transform patient outcomes in oncology and autoimmune treatment.

As they prepare for this new chapter, all eyes will be on HanchorBio, awaiting their progress in clinical trials and their ability to execute on global partnerships that will define their future.

For more details about HanchorBio and its innovative approaches, visit HanchorBio Official Site.